Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses

摘要

BackgroundEfficacy of inhaled loxapine 5 or 10 mg in treating agitation was shown using the Positive and Negative Syndrome Scale – Excited Component (PANSS-EC) in two Phase III randomised, double-blind, placebo-controlled trials in 344 agitated patients with schizophrenia and 314 patients with bipolar I disorder (Clinicaltrials.gov: , ).